Chemical manufacturers welcome ozone bill
The American Chemistry Council has welcomed new legislation that aims to help states comply with ozone standards.
The Ozone Standards Implementation Act of 2016 would update how the U.S. Environmental Protection Agency (EPA) addresses ozone requirements in the Clean Air Act. Introduced by U.S. Senators Shelley Moore Capito (R-West Virginia) and Jeff Flake (R-Arizona), it would elongate the time between each review of national ambient air quality standards from five years to 10 years, making it easier and more cost-effective for states to comply.
It also phases in implementation of the 2008 and 2015 ozone standards, extending the compliance date for the 2015 standards to 2025, and directs the EPA to submit a report to Congress within two years regarding the impact of foreign pollution sources on compliance.
Tested method helps determine health risks of chemicals
Researchers have tested a new method to help define health risks for more than 80,000 chemicals in commerce and the environment.
The approach uses computational toxicology and quantitative high-throughput screening (qHTS) technologies to help government regulatory agencies such as the U.S. Environmental Protection Agency prioritize which chemicals to examine for potential hazardous effects to humans.
The pilot program found that benzo[k]fluoranthene may induce DNA damage and steatosis through in vitro calculations. The researched was published in the journal Risk Analysis.
Lubrizol LifeSciences to add commercial manufacturing to Pennsylvania plant
Lubrizol LifeSciences, part of specialty chemical company The Lubrizol Corporation, is adding commercial drug product manufacturing capacity at its Particle Sciences facility in Bethlehem, Pennsylvania, in a multi-million-dollar expansion project.
The 18,000-square-foot facility will include both sterile and non-sterile space with complete lyophilization and filling operations. Among other things, the facility will be tailored for nano-milling and other complex processes.
Particle Sciences provides drug development services, focusing on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products and solid solutions.